Bio-Rad Laboratories, Inc. (NYSE:BIO) Forecasted to Post Q1 2025 Earnings of $2.39 Per Share

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research raised their Q1 2025 earnings per share estimates for shares of Bio-Rad Laboratories in a research note issued on Monday, April 15th. Zacks Research analyst R. Anand now expects that the medical research company will earn $2.39 per share for the quarter, up from their prior estimate of $2.35. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.41 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2025 earnings at $3.83 EPS.

A number of other brokerages have also recently issued reports on BIO. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Royal Bank of Canada decreased their price target on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. UBS Group increased their price target on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, February 16th. Finally, Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $468.00.

Bio-Rad Laboratories Price Performance

Shares of BIO stock opened at $290.78 on Wednesday. Bio-Rad Laboratories has a twelve month low of $261.59 and a twelve month high of $489.36. The business has a fifty day simple moving average of $331.66 and a 200 day simple moving average of $321.00. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14. The company has a market cap of $8.29 billion, a P/E ratio of -13.53 and a beta of 0.87.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The business had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. During the same period in the prior year, the company earned $3.31 EPS. Bio-Rad Laboratories’s revenue for the quarter was down 6.7% on a year-over-year basis.

Institutional Trading of Bio-Rad Laboratories

Hedge funds have recently made changes to their positions in the company. Quarry LP bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at $27,000. Farther Finance Advisors LLC increased its stake in Bio-Rad Laboratories by 42.3% in the 2nd quarter. Farther Finance Advisors LLC now owns 101 shares of the medical research company’s stock worth $38,000 after acquiring an additional 30 shares during the last quarter. Sound Income Strategies LLC bought a new position in Bio-Rad Laboratories in the 1st quarter worth about $38,000. Gladius Capital Management LP increased its stake in Bio-Rad Laboratories by 65.8% in the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the last quarter. Finally, Principal Securities Inc. bought a new position in Bio-Rad Laboratories in the 4th quarter worth about $41,000. 65.24% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the business’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the sale, the executive vice president now directly owns 6,942 shares in the company, valued at $2,332,512. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 17.50% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.